Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Ketamine petition receives over 3,000 signatures
Stray dog
Ketamine is critical for control of zoonotic diseases like rabies.
Proposal to reschedule drug to be considered this week 

A WSAVA petition calling for ketamine not to be placed under international control has received over 3,000 signatures.

In 2014, China proposed to reclassify the drug to Schedule 1 following widespread misconception that it is only a ‘recreational drug’.

Yet a review by the World Health Organisation (WHO) concluded that ketamine abuse does not pose a global public health threat, and that such control would limit access to those who most need it as a life-saving anaesthetic.

This week, delegates at the 29th UN Convention on Narcotic Drugs (CND) (14-22 March, Vienna) will meet to decide between the two opposite proposals.

In an open letter, the WSAVA urge the CND to follow the recommendations of the WHO. In it they write:

“The proposal for international control stems from the widespread misconception that it is only a 'recreational drug.' This is an inaccurate view and devalues the contribution that ketamine makes to to human and animal health. The WSAVA believes that it is an essential medicine.

“Ketamine is a remarkably safe anaesthetic which has been used worldwide for more than 50 years. It does not depress respiration or the circulation.  It can be used without oxygen, ventilators and electricity supply and support systems required for other anaesthetics.  

“These characteristics make it the only anaesthetic suitable for both medical and veterinary use in lower and middle income countries.”

As well as having particular value ‘in the field’ - for trauma, traffic and sporting injuries, ketamine is the most common and often only product for steralization initiatives. It also plays a huge role in feral cat/dog populations and is critical for control of zoonotic diseases like rabies.

The WSAVA conclude: “The WSAVA believes that medical and veterinary professionals should continue to have access to ketamine under the current scheduling controls and calls on concerned individuals to support our campaign to allow access to this essential medicine.”

To support the campaign and sign the petition visit: www.change.org.

Become a member or log in to add this story to your CPD history

FIVP launches CMA remedies survey

News Story 1
 FIVP has shared a survey, inviting those working in independent practice to share their views on the CMA's proposed remedies.

The Impact Assessment will help inform the group's response to the CMA, as it prepares to submit further evidence to the Inquiry Group. FIVP will also be attending a hearing in November.

Data will be anonymised and used solely for FIVP's response to the CMA. The survey will close on Friday, 31 October 2025. 

Click here for more...
News Shorts
CMA to host webinar exploring provisional decisions

The Competition and Markets Authority (CMA) is to host a webinar for veterinary professionals to explain the details of its provisional decisions, released on 15 October 2025.

The webinar will take place on Wednesday, 29 October 2025 from 1.00pm to 2.00pm.

Officials will discuss the changes which those in practice may need to make if the provisional remedies go ahead. They will also share what happens next with the investigation.

The CMA will be answering questions from the main parties of the investigation, as well as other questions submitted ahead of the webinar.

Attendees can register here before Wednesday, 29 October at 11am. Questions must be submitted before 10am on 27 October.

A recording of the webinar will be accessible after the event.